Histone deacetylase inhibitors in cancer: What have we learned?

E-ISSN： 1097-0142|121|8|1164-1167

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.8, 2015-04, pp. : 1164-1167

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic vaccines for prostate cancer: what have we learned?

By Gulley James L

Therapy, Vol. 5, Iss. 1, 2008-01 ,pp. : 3-5

Future Medicine

Access to resources Recommend Favorite

Contralateral biopsy in the management of testicular cancer: what we have learned and what we need to improve

ANDROLOGY, Vol. 3, Iss. 1, 2015-01 ,pp. : 99-101

John Wiley & Sons Inc

Access to resources Recommend Favorite

Histone deacetylase inhibitors for the treatment of breast cancer: recent trial data

By Truong Thach-Giao Munster Pamela

Clinical Investigation, Vol. 3, Iss. 6, 2013-06 ,pp. : 557-569

Future Science

Access to resources Recommend Favorite

Primary therapy in breast cancer: what have we learned from landmark trials?

By Bozza Claudia Osa Etin-Osa Puglisi Fabio

Women's Health, Vol. 9, Iss. 6, 2013-11 ,pp. : 583-593

Future Medicine

Access to resources Recommend Favorite

WONCA Europe in Vienna 2012-what have we learned?

By Reis Shmuel

Family Practice, Vol. 29, Iss. 6, 2012-12 ,pp. : 623-625

Oxford University Press

Access to resources Recommend Favorite